Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?


Eskazan A. E. , Ozmen D.

EXPERT REVIEW OF HEMATOLOGY, vol.10, no.7, pp.583-586, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 10 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1080/17474086.2017.1339599
  • Title of Journal : EXPERT REVIEW OF HEMATOLOGY
  • Page Numbers: pp.583-586